Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
E-Power Resources Inc. Announces Flow-Through and Hard Dollar Private Placements to Fund Summer Work Program
Juggernaut Exploration: Advancing High-grade Precious Metals Assets in Northern BC’s Golden Triangle
New INNspired Article Spotlights Rare Earth Recycling as a Strategic Investment Opportunity in U.S. Critical Mineral Supply Chain
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
